- Share-swap deal brings Naishadh Shah into Eris’ Top-10 Shareholder Ranks
- Shah to join senior management, Lead Swiss Parenterals as Managing Director
NE BUSINESS BUREAU
MUMBAI, NOV 26
Eris Lifesciences Limited (BSE: 540596; NSE: ERIS) has announced that its Board of Directors has approved the acquisition of the remaining 30% stake in Swiss Parenterals Limited, completing full ownership of the subsidiary. The transaction will be executed through a share-swap arrangement, under which Eris will issue preferential equity shares to the seller, Naishadh Shah, making him one of Eris’ Top-10 shareholders with long-term strategic alignment.
Along with his enhanced shareholding, Shah will formally join the Eris senior management team and is proposed to be appointed Managing Director of Swiss Parenterals, strengthening the company’s leadership bench as it accelerates its global ambitions.
“On behalf of all Eris shareholders, I am delighted to welcome Mr. Naishadh Shah to the community of Erisians,” said Amit Bakshi, Chairman & Managing Director, Eris Lifesciences Ltd. “FY27 is poised to be a breakout year for our international business, and Naishadh’s leadership will be pivotal to that growth.”
Expressing his enthusiasm, Naishadh Shah, Wholetime Director, Swiss Parenterals Ltd., said, “It is exciting to align with Eris as a long-term shareholder and senior management member. The combined strength of Eris’ manufacturing ecosystem in Ahmedabad and Bhopal with Swiss Parenterals’ capabilities will significantly enhance our value to global customers. I look forward to the next phase of this growth journey.”
The acquisition reinforces Eris’ commitment to expanding its international footprint and strengthening vertically integrated capabilities across key therapeutic segments.
